AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase III clinical study titled A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator’s Choice of ...

Use of durvalumab before and after radical cystectomy improved outcomes for patients with muscle-invasive bladder cancer, according to results of the randomized phase 3 NIAGARA trial.The regimen ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

MATTERHORN supports the global adoption of perioperative durvalumab plus FLOT as a new standard for patients with localized gastric and gastroesophageal junction adenocarcinoma,” said Yelena Y.

The team analyzed a cohort of 81 consecutive patients who underwent chemoradiation with durvalumab for locally advanced unresectable NSCLC between November 2013 and March 2020.

The positive findings for durvalumab continued with TFST, which was not reached; however, this was 8.3 (95% CI, 4.8-11.8) months for those who did not receive durvalumab.

The supplemental Biologics License Application for the gastric/GEJ cancer indication is supported by data from the double-blind, placebo-controlled MATTERHORN trial.

Durvalumab combined with transarterial chemoembolization and bevacizumab lengthened PFS among certain patients with hepatocellular carcinoma, according to the agent’s manufacturer. Topline data ...

Meeting Coverage > IGCS Durvalumab-CRT Pairing Disappoints in Locally Advanced Cervical Cancer — Still, CALLA trial findings "will inform future strategies to improve treatment," researcher says ...

The US Food and Drug Administration (FDA) has granted priority review to durvalumab for the treatment of patients with resectable, stage II-IVA gastric or gastroesophageal junction (GEJ) cancer.

Durvalumab therapy after chemoradiotherapy significantly improves overall and progression-free survival in patients with limited-stage small cell lung cancer (SCLC). The median overall survival ...

The estimated mean OS was 55.9 months and 33.4 months for durvalumab and placebo, respectively; 57% of durvalumab-treated patients were alive at 3 years compared with 48% of the placebo group.